• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

A Surprise Uppercut

Biotech Letter

Remember when Muhammad Ali got knocked down by Joe Frazier? Well, Merck (MRK) just had its Ali moment, courtesy of a plucky little biotech named Summit Therapeutics (SMMT).

Ivonescimab, a cancer drug developed by this relatively under-the-radar biotech company, just gave Merck's golden goose, Keytruda, a serious run for its money—and not by a small margin.

In a recent announcement, Summit Therapeutics revealed that Ivonescimab reduced the risk of disease progression or death by a whopping 49% compared to Keytruda. Let that sink in for a moment

In the trial, aptly named HARMONi-2 (these folks love their capitalization), Ivonescimab held tumor progression at bay for a median of 11.1 months. Keytruda? A mere 5.8 months.

Needless to say, Summit just landed a haymaker that has Merck seeing stars.

Now, before you rush to dump your Merck stock faster than a hot potato, let's put this in perspective. The trial was conducted in China with Summit's collaboration partner, Akeso. It's a significant result, no doubt, but we're not talking FDA approval just yet.

Still, Wall Street took notice. Summit's stock shot up 61% in Monday's premarket while Merck's stock took a hit.

But here's where it gets interesting. Merck's been the undisputed heavyweight champ of pharma for years, with Keytruda as its championship belt. This wonder drug has been laying billion-dollar eggs for nearly a decade, and the nest keeps growing.

In 2022, the Keytruda market was valued at $20.8 billion, and by 2023, it raked in a staggering $25.01 billion.

With AbbVie’s (ABBV) Humira out of the running, projections for 2024 now peg Keytruda as the top-ranked drug worldwide, with sales expected to surpass $27 billion.

By 2032, it's expected to soar to $45.9 billion, with a compound annual growth rate (CAGR) of 9.20% from 2024 to 2032.

Just last quarter, Keytruda accounted for a whopping 45% of Merck’s $16.1 billion revenue—that’s $7.3 billion from a single drug. Talk about putting all your eggs in one basket.

And therein lies the rub. Keytruda's patent expires in 2028. That's not tomorrow, but in the pharma world, it's just around the corner.

It's like watching the countdown timer on a bomb in an action movie - you know it's coming, but you can't look away.

Merck's not blind to this. They've been diversifying as fast as they could.

Their next largest product, Gardasil, brought in $2.5 billion last quarter, growing at a modest 4%. Not Keytruda numbers, but nothing to sneeze at.

They're also betting big on new drugs. There's Winrevair, a treatment for pulmonary arterial hypertension that could bring in up to $11 billion by 2029.

Then there's Capvaxive, a pneumococcal vaccine that could hit $1 billion in sales by 2027. And let's not forget their $5.5 billion deal with Daiichi Sankyo for three antibody-drug conjugates.

So, what's the play here? Merck's trading at 15 times next year's earnings. That's like finding a designer suit at a thrift store price.

The stock's up 5.3% this year, lagging behind the S&P 500's 16% growth. Some might see a bargain, others a warning sign.

Here's my take: Merck's got challenges, no doubt. But they've also got a track record of success and a pipeline that could make a pharmacist drool.

If you've got the patience of Job and the stomach for biotech's wild rides, Merck could be a solid long-term play.

But don't take your eyes off Summit Therapeutics. They’ve just proved they can punch above their weight class.

Besides, in this high-stakes arena of biotech, where one breakthrough can knock the competition to the mat, it’s the unexpected contenders that often deliver the biggest surprises.  So, keep your eyes on the ring—the next round promises to be a thriller.

 

 

Share this entry
  • Share on Facebook
  • Share on X
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail
https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-09-12 12:00:362024-09-12 12:26:48A Surprise Uppercut

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Link to: Trade Alert - (GLD) September 12, 2024 - BUY Link to: Trade Alert - (GLD) September 12, 2024 - BUY Trade Alert - (GLD) September 12, 2024 - BUY Link to: September 12, 2024 Link to: September 12, 2024 September 12, 2024
Scroll to top